Zachary Bessette

GU Oncology Now

A <a href="https://meetings.asco.org/abstracts-presentations/218078" target="_blank" rel="noopener">post hoc analysis</a> of the IMvigor130 trial examined overall survival (OS) outcomes by response during first-line induction atezolizumab or placebo plus platinum-based chemotherapy induction for patients with metastatic urothelial carcinoma (mUC).Results of the analysis are being presented at the American Society of Clinical Oncology 2023 Annual Meeting.The international, randomized, phase 3 IMvigor130 study evaluated atezolizumab plus platinum-based chemotherapy (Arm A) versus atezolizumab monotherapy (Arm B) and placebo plus platinum-based chemotherapy (Arm C) in patients with mUC. The previously reported final analysis showed that improved OS in Arm A versus Arm C in the intention-to-treat population did not reach statistical significance.In the initial study, investigators prespecified whether patients received gemcitabine plus cisplatin or gemcitabine plus carboplatin, and this information was used as a randomization stratification factor. Patients without progressive disease were allowed to continue atezolizumab or placebo after 4 to 6 cycles of gemcitabine plus platinum-based chemotherapy.Enrique Grande, MD, PhD, MSc, and colleagues conducted a post hoc analysis that evaluated postinduction (week 18) OS in patients who completed 4 to 6 cycles of chemotherapy followed by at least 1 dose of atezolizumab or placebo and who had a best response of at least stable disease without progressive disease at any time&mdash;up to and including the week 18 tumor assessment.The time from last patient randomization to the data cutoff (August 31, 2022) was 49 months. Researchers found that OS improvements favoring Arm A over Arm C were greater for patients treated with cisplatin rather than carboplatin. They noted that in the cisplatin subgroup, OS rates at 36 months were 47% and 34% for Arms A and C, respectively, for patients who achieved at least stable disease during induction.&ldquo;In this post hoc analysis, the initial response to induction therapy did not seem to impact OS outcomes,&rdquo; authors of the study concluded. &ldquo;Consistent with prior analyses, these data suggest that cisplatin-treated patients may derive a greater benefit from the addition of atezolizumab than carboplatin-treated patients.&rdquo;

IMvigor130: Updated OS Data From the Final Analysis

American Society of Clinical Oncology 2023 Annual Meeting

ASCO 2023

A post hoc analysis of the IMvigor130 trial examined OS outcomes during first-line induction for patients with mUC.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe